Side-by-side financials for CHRS and RVMD. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CHRS | RVMD |
|---|---|---|
| Market cap | - | $32.71 B |
| US-listed rank | - | #439 |
| Revenue (latest FY) | $42.17M | $0.00 |
| Net income (latest FY) | $168.02M | -$1.13B |
| Net margin | 398.4% | - |
| SEC filings | 898 | 782 |
In their latest fiscal years, Coherus BioSciences, Inc. reported $42.17M in revenue while Revolution Medicines, Inc. reported $0.00.
Full pages: Coherus BioSciences, Inc. and Revolution Medicines, Inc., or browse the full rankings.